Caplin Point Lab declines after arm receives form-485 with 10 observations from USFDA

Caplin Point Laboratories fell 2.38% to Rs 2,497.25 after the company said that the USFDA conducted an unannounced inspection of its subsidiary Caplin Steriles’ injectable and ophthalmic manufacturing facility at Gummidipoondi, Tamil Nadu.
Read more at the source

Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.